Dr. Lawrence Stanton joined QBRI in 2019 with more than 30 years of research experience in industry and academia. His research is focused on dissecting the molecular pathways that underly neurodevelopmental disorders, including autism. After earning a PhD in biochemistry at Stony Brook University (USA), he completed a post-doctoral fellowship in cancer biology at University of California San Francisco (USA) under the guidance of Nobel Laureate, Dr. Michael Bishop.
At QBRI the Stanton lab is generating induced pluripotent stem cells (iPSC) from patients with neurodevelopmental disorders. These patient-specific iPSC are converted into neural cell types and organoids, thus providing an opportunity to understand the molecular pathology of diseases such as autism and establishing a foundation for the development of diagnostics and therapeutics to treat patients with neurodevelopmental disorders.
Scios Inc1990 - 2000
Geron Corp2001 - 2002
Genome Institute of Singapore2002 - 2016
Humacyte Inc., USA2017 - 2019
Stony Brook University (USA)
University of California San Francisco (USA)
Sheila M, Narayanan, G, Ma S, Tam WL, Chai J and Lawrence W Stanton Neurobiology of Disease 124, p1-13 (2019)2019
Wang J, Jenjaroenpun P, Bhinge A, Angarica VE, Del Sol A, Nookaew I, Kuznetsov VA, and Lawrence W Stanton Genome Research 27(11), p1783-1794 (2017)2017
Bhinge A, Namboori S, and Lawrence W. Stanton Stem Cell Reports 8(4), p856-69 (2017)2017
Lin L, Goke, J, Cukuroglu E, Dranias MR, Van Dongen AMJ, and Lawrence W. Stanton Cell Reports 15(11), p2411-26 (2016)2016
Bhinge A, Namboori S Angela Bithell, Soldati AC, Buckley NJ, Lawrence W. Stanton Stem Cells 34(1), p124-34 (2016)2016
Bhinge A, Poschman J, Tian XF, Loh JH, Traczyk A, Prabhakar S, and Lawrence W. Stanton EMBO J 33(11), p1271-83 (2014)2014
Ng SY, Bogu G, Soh BS, and Lawrence W. Stanton Molecular Cell 51(3), p349-59 (2013)2013